917
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Astellas Pharma's recently active trials. Comparator arms are excluded.
- Pembrolizumab13 trials
- zolbetuximab9 trials
- Oxaliplatin9 trials
- Fezolinetant7 trials
- Carboplatin6 trials
- Leucovorin6 trials
Upcoming readouts
Next primary completion dates among Astellas Pharma's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Oct 2027A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney DiseasePhase 3
- Nov 2027A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-inva…Phase 2
- Sept 2028LUCERNA: A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Canc…Phase 3
- Aug 2029A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX …Phase 3
- Mar 2030Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in …Phase 3
- Jun 2030A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Can…Phase 3
Top therapeutic areas
Conditions studied most often across Astellas Pharma's recently active trials.
- Hot Flashes7 trials
- Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma5 trials
- Prostate Cancer5 trials
- Urothelial Cancer5 trials
- Type 2 Diabetes Mellitus5 trials
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer4 trials
Astellas Pharma pipeline by phase
The main study drugs across 51 active trials Astellas Pharma leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 38 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| zolbetuximab | 6 | 1 | Jun 2027 est. | NCT06901531 · NCT03653507 · NCT03504397 |
| Setidegrasib | 4 | 3 | May 2027 est. | NCT07566052 · NCT07409272 · NCT07395024 |
| ASP2138 | 3 | 3 | Jan 2028 est. | NCT07673887 · NCT07024615 · NCT05365581 |
| Fezolinetant | 3 | 1 | Feb 2027 est. | NCT06440967 · NCT07783282 · NCT07602530 |
| Gilteritinib | 3 | 1 | Jul 2028 est. | NCT03182244 · NCT07140016 · NCT05520567 |
| Enzalutamide | 2 | — | Jul 2029 est. | NCT04076059 · NCT02960022 |
| mirabegron | 1 | — | — | NCT05621616 |
| Roxadustat | 1 | 1 | Oct 2027 est. | NCT05970172 |
Phase 22 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| ASP5541 | 2 | 2 | Dec 2028 est. | NCT07005154 · NCT07339267 |
| Resamirigene bilparvovec | 1 | — | — | NCT03199469 |
Phase 117 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| 14C-labeled ASP3082 | 1 | — | Oct 2026 est. | NCT07773129 |
| ASP1002 | 1 | 1 | Apr 2030 est. | NCT05719558 |
| ASP2020 | 1 | 1 | Sept 2029 est. | NCT07734064 |
| ASP2246 | 1 | 1 | Feb 2030 est. | NCT07318714 |
| ASP2390 | 1 | — | — | NCT04184895 |
| ASP2767 | 1 | 1 | Jul 2030 est. | NCT07770685 |
| ASP2998 | 1 | 1 | Jun 2029 est. | NCT07287995 |
| ASP388B | 1 | 1 | Feb 2030 est. | NCT07730021 |
| ASP546C | 1 | 1 | Jul 2029 est. | NCT07488676 |
| ASP5834 | 1 | 1 | Nov 2028 est. | NCT07094204 |
| ASP7317 | 1 | 1 | Dec 2027 est. | NCT03178149 |
| Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells | 1 | — | Mar 2029 est. | NCT03167203 |
| Methylprednisolone | 1 | 1 | Oct 2027 est. | NCT07052929 |
| PRL-02 injection | 1 | 1 | May 2029 est. | NCT04729114 |
| VIR-5500 | 1 | 1 | Sept 2027 est. | NCT05997615 |
| XNW27011 | 1 | — | Dec 2026 est. | NCT06792435 |
| zocaglusagene nuzaparvovec | 1 | — | Feb 2035 est. | NCT04174105 |
Phase 42 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Enfortumab vedotin | 5 | 3 | Dec 2026 est. | NCT06862219 · NCT07566156 · NCT04223856 |
| avacincaptad pegol | 1 | — | Jun 2027 est. | NCT06970665 |
Derived from 51 active trials Astellas Pharma leads; 51 name an intervention, folding into 29 phased drugs. 2 interventions carry no registry phase (observational studies, tests and devices) and are not shown. This is ComplyRx's reading of the registry, not Astellas Pharma's own pipeline disclosure.
Astellas Pharma trials
The 50 most significant of Astellas Pharma's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Learn How ASP3082 is Processed in Healthy MenNCT0777312914C-labeled ASP3082 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 8 est. | 31 Oct 2026 |
| XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.NCT06792435XNW27011 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 240 est. | 30 Dec 2026 |
| A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerNCT06862219Enfortumab Vedotin | Phase 4 | Locked · track to reveal | OngoingRecruiting | 100 est. | 31 Dec 2026 |
| CANDLELIGHTA Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical PracticeNCT07602530Fezolinetant | — | Locked · track to reveal | OngoingRecruiting | 238 est. | 28 Feb 2027 |
| A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerNCT07783282fezolinetant | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 56 est. | 30 Apr 2027 |
| A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy AdultsNCT07395024Setidegrasib | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 54 est. | 2 May 2027 |
| A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationNCT06970665avacincaptad pegol | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 17 est. | 30 Jun 2027 |
| ILUSTROA Study of Zolbetuximab (IMAB362) in Adults With Gastric CancerNCT03505320zolbetuximab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 143 est. | 30 Jun 2027 |
| A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe DiseaseNCT06150820 | Na | Locked · track to reveal | OngoingActive, not recruiting | 119 est. | 30 Jun 2027 |
| A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV InjectionNCT06011954Enfortumab Vedotin | — | Not yet scored | OngoingRecruiting | 202 est. | 31 Jul 2027 |
| Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerNCT05997615VIR-5500 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 437 est. | 29 Sept 2027 |
| A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney DiseaseNCT05970172Roxadustat | Phase 3 | Locked · track to reveal | OngoingRecruiting | 100 est. | 30 Oct 2027 |
| Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need VentilatorsNCT07052929ASP2957 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 9 est. | 31 Oct 2027 |
| A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderNCT07475806Enfortumab Vedotin | Phase 2 | Locked · track to reveal | OngoingRecruiting | 240 est. | 30 Nov 2027 |
| EXCELA Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle ConditionNCT06581146 | — | Not yet scored | OngoingRecruiting | 50 est. | 31 Dec 2027 |
| A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal CancerNCT07024615ASP2138 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 25 est. | 31 Jan 2028 |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerNCT05365581ASP2138 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 398 est. | 31 May 2028 |
| EVOLVEA Study to Learn How Stargardt-type Eye Conditions Progress in Children and AdultsNCT07425574 | — | Not yet scored | OngoingRecruiting | 90 est. | 31 Jul 2028 |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaNCT05520567Gilteritinib | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 70 est. | 31 Jul 2028 |
| LUCERNAA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerNCT06901531zolbetuximab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 500 est. | 30 Sept 2028 |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsNCT07094204ASP5834 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 364 est. | 30 Nov 2028 |
| A Study of ASP3082 in Adults With Advanced Solid TumorsNCT05382559Setidegrasib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 681 est. | 31 Dec 2028 |
| A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate CancerNCT07339267ASP5541 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 12 est. | 31 Dec 2028 |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerNCT04729114PRL-02 injection | Phase 1 | Locked · track to reveal | OngoingRecruiting | 174 est. | 31 May 2029 |
| A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsNCT07287995ASP2998 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 428 est. | 30 Jun 2029 |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsNCT07488676ASP546C | Phase 1 | Locked · track to reveal | OngoingRecruiting | 150 est. | 31 Jul 2029 |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022enzalutamide | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 900 est. | 31 Jul 2029 |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerNCT07409272Setidegrasib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 614 est. | 31 Aug 2029 |
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)NCT07140016gilteritinib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 31 Dec 2029 |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsNCT07730021ASP388B | Phase 1 | Locked · track to reveal | OngoingRecruiting | 392 est. | 28 Feb 2030 |
| A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a StrokeNCT07318714ASP2246 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 84 est. | 28 Feb 2030 |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)NCT07566156Enfortumab vedotin | Phase 3 | Locked · track to reveal | OngoingRecruiting | 390 est. | 31 Mar 2030 |
| A Study of ASP1002 in Adults for Treatment of Solid TumorsNCT05719558ASP1002 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 798 est. | 30 Apr 2030 |
| A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationNCT07566052Setidegrasib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 356 est. | 30 Jun 2030 |
| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamageNCT07770685ASP2767 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 156 est. | 31 Jul 2030 |
| A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.NCT06902545zolbetuximab | — | Not yet scored | OngoingRecruiting | 377 est. | 31 Jul 2030 |
| A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic AtrophyNCT06779773Avacincaptad pegol (ACP) | — | Not yet scored | OngoingRecruiting | 500 est. | 31 Oct 2030 |
| A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)NCT07619105Vesomni | — | Not yet scored | OngoingNot yet recruiting | 600 est. | 30 Nov 2030 |
| A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerNCT07673887ASP2138 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 570 est. | 28 Feb 2031 |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154ASP5541 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 218 est. | 31 May 2032 |
| FORTISGene Transfer Study in Patients With Late Onset Pompe DiseaseNCT04174105zocaglusagene nuzaparvovec | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 11 est. | 28 Feb 2035 |
| A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerNCT03816163zolbetuximab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 393 est. | 31 Aug 2026 |
| A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic CancerNCT06396091zolbetuximab | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 12 est. | 31 Jul 2026 |
| GRACEA Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During MenopauseNCT07455812Fezolinetant | — | Locked · track to reveal | Completed | 105 est. | 16 Jul 2026 |
| A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyNCT06440967Fezolinetant | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 982 est. | 30 Jun 2026 |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid TumorsNCT06364696ASP4396 | Phase 1 | Locked · track to reveal | StoppedTerminated | 60 est. | 17 Jun 2026 |
| Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid ArthritisNCT03971253Peficitinib | — | Not yet scored | Completed | 3,000 est. | 29 May 2026 |
| A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsNCT05083481ASP1570 | Phase 1 | Locked · track to reveal | StoppedTerminated | 226 est. | 11 May 2026 |
| Starlight 3A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through MenopauseNCT06206421Fezolinetant | Phase 3 | Locked · track to reveal | Completed | 277 est. | 19 Mar 2026 |
| A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's SyndromeNCT06544642ASP5502 | Phase 1 | Locked · track to reveal | StoppedTerminated | 116 est. | 5 Mar 2026 |